Primary Sjogren’s Syndrome – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Primary Sjogren’s Syndrome – Drugs In Development, 2024 report and make more profitable business decisions.
Primary Sjogren’s Syndrome is a common chronic autoimmune disorder that affects the lacrimal and salivary glands, and some may develop extra glandular involvement of joints, GI tract, lungs, skin, CNS, and kidneys. Dry eyes and dryness of mouth are characteristic features of this condition. Joint pain, skin rashes, and dry cough are some other symptoms. Eye drops treat dry eyes which are composed of corticosteroids. Hydration to treat dry mouth and preventive care to treat complications associated.
The Primary Sjogren’s Syndrome drugs in development market research report provide comprehensive information on the therapeutics under development for Primary Sjogren’s Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Primary Sjogren’s Syndrome and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Primary Sjogren's Syndrome | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 13 molecules, with 13 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Primary Sjogren’s Syndrome therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Primary Sjogren’s Syndrome pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Primary Sjogren’s Syndrome treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Argenx SEAstraZeneca Plc
Bristol-Myers Squibb Co
Innovent Biologics Inc
Johnson & Johnson
Novartis AG
OSE Immunotherapeutics SA
RemeGen Co Ltd
Rophibio Inc
Samjin Pharm Co Ltd
Sanofi
Simcere Pharmaceutical Group Ltd
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Primary Sjogren's Syndrome reports